Commercial Versus Compounded Preparations in Pediatric Ophthalmology

Paediatr Drugs. 2024 Sep;26(5):475-477. doi: 10.1007/s40272-024-00642-w. Epub 2024 Jun 27.

Abstract

Many conditions managed by pediatric ophthalmologists are rare diseases, and even if pharmacological treatments are available, these have often not been evaluated in children. Off-label prescribing is a common practice in pediatric ophthalmology. In addition, there is often no commercial case for the production of a medicine that may only be used for a small number of patients worldwide. Compounded preparations prepared locally are therefore still in frequent use, although it is known that production may not meet stringent quality assurance standards. For several indications, commercial preparations, evaluated in rigorous clinical trials with children, are now available. Myopia management is joining the list of these indications, with low-concentration atropine formulations derived from recent clinical trials in Australia, USA, and Europe now entering the market. This short article gives an overview of the background and recent developments of compounded and commercial preparations for use in pediatric ophthalmology.

Publication types

  • Review

MeSH terms

  • Child
  • Drug Compounding* / methods
  • Drug Compounding* / standards
  • Humans
  • Off-Label Use
  • Ophthalmic Solutions / chemistry
  • Ophthalmic Solutions / standards
  • Ophthalmology* / standards
  • Pediatrics / standards

Substances

  • Ophthalmic Solutions